Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases
Proteomics and metabolomics are two emerging fields that hold promise to shine light on the molecular mechanisms causing neurodegenerative diseases. Research in this area may reveal and quantify specific metabolites and proteins that can be targeted by therapeutic interventions intended at halting o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.792227/full |
| _version_ | 1823961211320926208 |
|---|---|
| author | Artur Schumacher-Schuh Artur Schumacher-Schuh Andrei Bieger Wyllians V. Borelli Makayla K. Portley Paula Saffie Awad Sara Bandres-Ciga Sara Bandres-Ciga |
| author_facet | Artur Schumacher-Schuh Artur Schumacher-Schuh Andrei Bieger Wyllians V. Borelli Makayla K. Portley Paula Saffie Awad Sara Bandres-Ciga Sara Bandres-Ciga |
| author_sort | Artur Schumacher-Schuh |
| collection | DOAJ |
| description | Proteomics and metabolomics are two emerging fields that hold promise to shine light on the molecular mechanisms causing neurodegenerative diseases. Research in this area may reveal and quantify specific metabolites and proteins that can be targeted by therapeutic interventions intended at halting or reversing the neurodegenerative process. This review aims at providing a general overview on the current status of proteomic and metabolomic profiling in neurodegenerative diseases. We focus on the most common neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. We discuss the relevance of state-of-the-art metabolomics and proteomics approaches and their potential for biomarker discovery. We critically review advancements made so far, highlighting how metabolomics and proteomics may have a significant impact in future therapeutic and biomarker development. Finally, we further outline technologies used so far as well as challenges and limitations, placing the current information in a future-facing context. |
| first_indexed | 2024-12-17T17:00:13Z |
| format | Article |
| id | doaj.art-695ca329044843c2a9d32798986c77ad |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-17T17:00:13Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-695ca329044843c2a9d32798986c77ad2022-12-21T21:40:21ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-01-011210.3389/fneur.2021.792227792227Advances in Proteomic and Metabolomic Profiling of Neurodegenerative DiseasesArtur Schumacher-Schuh0Artur Schumacher-Schuh1Andrei Bieger2Wyllians V. Borelli3Makayla K. Portley4Paula Saffie Awad5Sara Bandres-Ciga6Sara Bandres-Ciga7Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, BrazilServiço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilDepartment of Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, BrazilServiço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilNeurodegenerative Disorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United StatesMovement Disorders Clinic, Centro de Trastornos de Movimiento (CETRAM), Santiago, ChileNeurodegenerative Disorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United StatesLaboratory of Neurogenetics, Molecular Genetics Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, United StatesProteomics and metabolomics are two emerging fields that hold promise to shine light on the molecular mechanisms causing neurodegenerative diseases. Research in this area may reveal and quantify specific metabolites and proteins that can be targeted by therapeutic interventions intended at halting or reversing the neurodegenerative process. This review aims at providing a general overview on the current status of proteomic and metabolomic profiling in neurodegenerative diseases. We focus on the most common neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. We discuss the relevance of state-of-the-art metabolomics and proteomics approaches and their potential for biomarker discovery. We critically review advancements made so far, highlighting how metabolomics and proteomics may have a significant impact in future therapeutic and biomarker development. Finally, we further outline technologies used so far as well as challenges and limitations, placing the current information in a future-facing context.https://www.frontiersin.org/articles/10.3389/fneur.2021.792227/fullproteomicsmetabolomicsAlzheimer's diseaseADParkinson's diseasePD |
| spellingShingle | Artur Schumacher-Schuh Artur Schumacher-Schuh Andrei Bieger Wyllians V. Borelli Makayla K. Portley Paula Saffie Awad Sara Bandres-Ciga Sara Bandres-Ciga Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases Frontiers in Neurology proteomics metabolomics Alzheimer's disease AD Parkinson's disease PD |
| title | Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases |
| title_full | Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases |
| title_fullStr | Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases |
| title_full_unstemmed | Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases |
| title_short | Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases |
| title_sort | advances in proteomic and metabolomic profiling of neurodegenerative diseases |
| topic | proteomics metabolomics Alzheimer's disease AD Parkinson's disease PD |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2021.792227/full |
| work_keys_str_mv | AT arturschumacherschuh advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT arturschumacherschuh advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT andreibieger advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT wylliansvborelli advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT makaylakportley advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT paulasaffieawad advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT sarabandresciga advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases AT sarabandresciga advancesinproteomicandmetabolomicprofilingofneurodegenerativediseases |